Compositions and methods for predicting hcv susceptibility to antiviral agents
AssigneeWisconsin Alumni Research Foundation
InventorsIsrar H. Ansari, Robert T. Striker
Life of this patent
Estimating the term…
Loading patent…
AssigneeWisconsin Alumni Research Foundation
InventorsIsrar H. Ansari, Robert T. Striker
Estimating the term…
Provided herein are methods for determining the susceptibility of a hepatitis C virus (HCV) in a patient to anti-viral agents, particularly cyclophilin inhibitors such as cyclosporine A. More particularly, provided herein are methods for determining the amino acid sequence within a region of the HCV NS5A protein and comparing the viral amino acid sequence to that of a reference strain, wherein the existence of at least one variation in the viral genome is indicative that the virus is more or less susceptible to anti-viral agents relative to the reference strain. Also provided are isolated polynucleotide molecules, replicons, and kits that can be used to assay the susceptibility of a particular HCV to an anti-viral agent.
A method for determining susceptibility of a hepatitis C virus (HCV) in a sample to an anti-viral agent, the method comprising determining the amino acid sequence within the HCV NS5A region and comparing said amino acid sequence to that of a reference strain, wherein the existence of at least one variation in the viral amino acid sequence is indicative that the virus is more or less susceptible to the anti-viral agent.
An isolated polynucleotide comprising a nucleic acid sequence that encodes for a region within the HCV NS5A protein having at least one variation in a consensus amino acid sequence corresponding to amino acid residues 305-328 of the reference HCV NS5 region of SEQ ID NO:3, wherein the mutated/variant consensus sequence encoded by the polynucleotide is KSRRFX1RALPVWAX2PX3X4X5PPLVEX6, wherein X1 is proline, isoleucine, arginine, or methionine;
A method for treating a HCV infection in an individual, the method comprising determining whether the HCV infection is susceptible to an anti-viral agent, and administering to the individual one or more anti-viral agents selected on the basis of the susceptibility determination, whereby the HCV infection is treated.
Dependencies are inferred from the claim text.